Abbott Laboratories stock: FDA approves new CardioMEMS capabilities
Published on 10/06/2026 at 20:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories said on October 5, 2026, that the U.S. Food and Drug Administration approved updates to its CardioMEMS HF System. The new capabilities are delivered through Abbott's CardioGuide HF App and are intended to give patients a more active role in managing heart failure. The announcement was published by Abbott MediaRoom.
New patient features
For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure readings directly on their smartphones, according to Abbott's release. The update also includes Dynamic Treatment Plan, a software feature that allows clinicians to create personalized medication adjustment plans based on changes in pulmonary artery pressure. Abbott said the CardioGuide HF App and Dynamic Treatment Plan are planned to become available later in 2026. The details were reported in the company's release.
